REFERENCES
1. Hasegawa A, Abe R. Recent advances in managing and understanding
Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Res2020; 9: F1000 Faculty Rev-612.
2. Shanbhag SS, Chodosh J, Fathy C, et al. Multidisciplinary care in
Stevens-Johnson syndrome. Ther Adv Chronic Dis 2020; DOI:
10.1177/2040622319894469.
3. Morton SMB, Atatoa Carr PE, Grant CC, et al. Cohort profile: growing
up in New Zealand. Int J Epidemiol. 2013; 42(1): 65-75.
DOI:10.1093/ije/dyr206
4. Abe J, Umetsu R, Mataki K, et al. Analysis of Stevens-Johnson
syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug
Event Report database. J Pharm Health 2016; 2: 14.
5. Abe J, Mataki K, Umetsu R, et al. Stevens-Johnson syndrome and toxic
epidermal necrolysis: The Food and Drug Administration adverse event
reporting system, 2004–2013. Allergol Int. 2015; 64: 277–9.
6. Milosavljević MN, Pejčić AV, Milosavljević JZ. A review of published
cases of Stevens-Johnson syndrome and toxic epidermal necrolysis
associated with the use of acetaminophen. Cutan Ocul Toxicol.2021; 40(3): 280-292. DOI: 10.1080/15569527.2021.1942896.
7. Lee QU. Hypersensitivity to antipyretics: pathogenesis, diagnosis,
and management.
Hong Kong Med J. 2017 ;23(4):395-403. DOI: 10.12809/hkmj166186.
8. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of
cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and
erythema multiforme. Arch Dermatol. 1993; 129: 92-96.
9. Borchers AT, Lee JL, Naguwa SM, et al. Stevens-Johnson syndrome and
toxic epidermal necrolysis. Autoimmun Rev. 2008; 7: 598-605.
10. Hsu DY, Brieva J, Silverberg NB, et al. Morbidity and Mortality of
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States
Adults. J Invest Dermatol 2016; 136: 1387-97.
11. Hsu DY, Brieva J, Silverberg NB, et al. Pediatric Stevens-Johnson
syndrome, and toxic epidermal necrolysis in the United States. J
Am Acad Dermatol 2017; 76: 811-7. e4.
12. Beck A, Cooney R, Gamelli RL, et al. Predicting mechanical
ventilation and mortality: early and late indicators in Steven-Johnson
syndrome and toxic epidermal necrolysis. J Burn Care Res 2016;
37: e47-e55.
13. Lebargy F, Wolkenstein P, Gisselbrecht M, et al. Pulmonary
complications in toxic epidermal necrolysis: a prospective clinical
study. Intensive Care Med 1997; 23: 1237-1244.
14. Kubo K, Azuma A, Kanazawa M, et al. Consensus statement for the
diagnosis and treatment of drug-induced lung injuries. Respir
Investig . 2013; 51: 260-277.